Navigation Links
VirtualScopics Announces Receipt of Notice from Nasdaq
Date:1/6/2012

ROCHESTER, N.Y., Jan. 6, 2012 /PRNewswire/ -- VirtualScopics, Inc., (NASDAQ: VSCP), a leading provider of image-based solutions to the pharmaceutical, biotechnology and medical device industries, announced today that on January 4, 2012 it received a notice from the NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 minimum bid price for continued listing of an issuer's common stock. 

In accordance with section 5810(c)(3)(A) of the NASDAQ Marketplace Rules, the Company has until July 2, 2012 to regain compliance. The Company can regain compliance with the minimum bid price rule if the bid price of its common stock closes at $1.00 or higher for a minimum of 10 consecutive business days during the 180-day period, although the NASDAQ Stock Market may, in its discretion, require the Company to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days before determining that it has demonstrated the ability to maintain long-term compliance.

Additionally, if compliance with this Rule cannot be demonstrated by July 2, 2012, NASDAQ will determine whether the Company meets the NASDAQ Capital Market initial listing criteria except for the bid price requirement. If the Company meets the initial listing criteria, NASDAQ will notify the Company that it has been granted an additional 180 calendar day compliance period. If the Company is not eligible for an additional compliance period, NASDAQ will notify the Company that its common stock will be delisted. At that time, the Company may appeal this determination to delist its securities to a Listing Qualification Panel.

The Company is actively pursuing a number of initiatives to bring the Company into compliance with the minimum share price requirement.

About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the Company's ability to regain compliance with Nasdaq listing standards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACTS:Investor Relations:Company Contact: 

Tim Ryan

Molly Henderson 

The Shoreham Group

Chief Business and Financial Officer, Sr. Vice President 

80 Eighth Ave, Ste 1107

500 Linden Oaks 

New York, NY 10011

Rochester, New York 14625 

+1 212 242 7777 Direct

+1 585 249.6231 

tryan@shorehamgroupllc.com

 


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
6. VirtualScopics Receives Issuance in Japan of Prominent Patent
7. VirtualScopics Added to Russell Microcap Index
8. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
9. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
10. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
11. VirtualScopics Revenues Hit Another Quarterly Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The IPF pipeline is very strong with a total of 97 ... Inc., Biogen and Sanofi are involved in the development of the IPF ... is in Phase III stage, 15 are in Phase II stage, 12 ...
(Date:3/24/2017)... March 24, 2017 A ReportsnReports.com report says, ... growing rapidly as the global sales of Adcetris and Kadcyla have ... the antibody drug conjugates market is driven by large number of ... wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... in Building 2. The clinic is the group’s second in New Braunfels and 22nd ... company’s second New Braunfels location brings things full circle for the group, “It’s crazy ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... ... 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play ... the minimum two times a day that dentists recommend. The ramifications of improper oral upkeep ... school and adults missing 164 million hours of work each year due to dental issues. ...
(Date:3/23/2017)... ... , ... March is National Kidney Month – the perfect time to pause ... good health. Every day, two kidneys filter about 120 to 150 quarts of blood. ... eliminating waste, regulating fluid levels and blood pressure, supporting bone health and promoting red ...
(Date:3/23/2017)... ... 2017 , ... The StayWell Company announced today that it ... StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, and ... programs for the delivery and improvement of disease management and that meet or ...
Breaking Medicine News(10 mins):